Geoffrey Beran Rose - Mar 1, 2023 Form 4 Insider Report for Pulmonx Corp (LUNG)

Role
Chief Commercial Officer
Signature
/s/ Lauren Cristina, Attorney-in-Fact for Geoffrey Beran Rose
Stock symbol
LUNG
Transactions as of
Mar 1, 2023
Transactions value $
-$13,302
Form type
4
Date filed
3/3/2023, 06:02 PM
Previous filing
Dec 5, 2022
Next filing
Jun 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LUNG Common Stock Sale -$4.82K -437 -0.24% $11.03 182K Mar 1, 2023 Direct F1, F2
transaction LUNG Common Stock Sale -$8.48K -769 -0.42% $11.03 181K Mar 1, 2023 Direct F3
transaction LUNG Common Stock Award $0 +78.9K +43.59% $0.00 260K Mar 1, 2023 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LUNG Employee Stock Option (right to buy) Award $0 +54K $0.00 54K Mar 1, 2023 Common Stock 54K $11.48 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on June 1, 2021.
F2 Includes 1,162 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on February 15, 2023.
F3 These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on March 1, 2022.
F4 Represents grant of Restricted Stock Units payable solely in common stock of the Issuer that vest over four years in equal quarterly installments beginning on March 1, 2023.
F5 The shares subject to the option vest in 48 equal monthly installments beginning on March 1, 2023.